Sign in

Jim Collins

Research Analyst at Portfolio Guru

Jim Collins is the Founding Partner and Chief Analyst at Portfolio Guru LLC, specializing in equity research and investment strategies focused on US-listed technology, consumer, and small-cap growth companies. He covers and actively tracks companies such as Tesla, Nio, Plug Power, Sirius XM, and Fisker, and is recognized on TipRanks for maintaining a consistent 60% success rate and generating average annualized returns over 15% across more than 400 public stock ratings. Collins began his finance career in the late 1990s, holding senior analyst roles at companies such as Lehman Brothers, Donaldson, Lufkin & Jenrette, and Matrix Asset Advisors before launching Portfolio Guru in 2010. He is FINRA-registered and holds Series 7, 24, 63, and 79 securities licenses, with frequent recognition as a top-performing independent equity analyst on major financial platforms.

Jim Collins's questions to EYES leadership

Question · Q3 2016

Jim Collins from Portfolio Guru asked for details on the new exclusive license and funding agreement, the current production rate for Argus II, and the company's capital raising plans given its cash runway through Q2 2017.

Answer

Chairman Dr. Robert Greenberg revealed the agreement is with a small tech company for image processing technology, supported by $450,000 in grants. CFO Tom Miller stated that Argus II production is paused to manage inventory, with manufacturing resources redirected to R&D. CEO Will McGuire and CFO Tom Miller confirmed they are exploring financing options and expect to make a decision in Q1 2017 to secure additional funding.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts